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TRMOME 1374 No. of Pages 15ReviewCancer-Associated PIK3CA Mutations in
Overgrowth DisordersRalitsa R. Madsen,1,2 Bart Vanhaesebroeck,3 and Robert K. Semple ,1,2,4,*Highlights
Cancer-associated activating PIK3CA
mutations, when occurring in isolation
during early development, cause a
spectrum of rare disorders character-
ized by asymmetric, and often severe,
excessive tissue growth and
malformations.
Tissues are not uniformly affected,
and, surprisingly, no excess of
PIK3CA-associated adult cancers
has been described.
Evidence that low-dose, repurposed
cancer therapies may offer effective
precision therapy is beginning to
emerge.
Mouse models driven by endogenous
expression of pathogenic, mosaic
PIK3CA alleles only partly recapitulate
the disease phenotype.
Although it is critical for normal cell
growth and survival, the role of PIK3CA
in early human development is poorly
characterized.
1Metabolic Research Laboratories,
Wellcome Trust-MRC Institute of
Metabolic Science, University of
Cambridge, Cambridge CB2 0QQ, UK
2The National Institute for Health
Research Cambridge Biomedical
Research Centre, Cambridge CB2
0QQ, UK
3UCL Cancer Institute, Paul O’Gorman
Building, University College London,
London WC1E 6DD, UK
4Centre for Cardiovascular Sciences,
Queens Medical Research Institute,
University of Edinburgh, Little France
Crescent, Edinburgh EH16 4TJ, UK
*Correspondence:
rsemple@exseed.ed.ac.uk
(R.K. Semple).PIK3CA is one of the most commonly mutated genes in solid cancers. PIK3CA
mutations are also found in benign overgrowth syndromes, collectively known
as PIK3CA-related overgrowth spectrum (PROS). As in cancer, PIK3CA
mutations in PROS arise postzygotically, but unlike in cancer, these mutations
arise during embryonic development, with their timing and location critically
inﬂuencing the resulting disease phenotype. Recent evidence indicates that
phosphoinositide 3-kinase (PI3K) pathway inhibitors undergoing trials in cancer
can provide a therapy for PROS. Conversely, PROS highlights gaps in our
understanding of PI3K’s role during embryogenesis and in cancer
development. Here, we summarize current knowledge of PROS, evaluate
challenges and strategies for disease modeling, and consider the implications
of PROS as a paradigm for understanding activating PIK3CA mutations in
human development and cancer.
Old Drivers in a New Context
Thirty years ago this year, in 1988, the enzyme phosphoinositide 3-kinase (PI3K) was identiﬁed
as a signal transducer downstream of activated cell surface growth factor receptors [1]. Its initial
identiﬁcation in the context of a viral oncogene immediately implicated the PI3K pathway in
cancer, and we now know that the genes encoding the p110a catalytic PI3K subunit and its
negative regulator, phosphatase and tensin homolog (PTEN), are among the most commonly
mutated in solid tumors. It has long been known that heterozygous mutations in PTEN are also
responsible for rare, cancer-prone syndromes collectively known as PTEN hamartoma
tumor syndrome (PHTS; see Glossary) [2]. It is only recently, however, that we have learned
of rare, but generally benign overgrowth syndromes caused by postzygotic activating
mutations in PIK3CA, the gene encoding p110a [3]. Collectively known as PIK3CA-related
overgrowth spectrum (PROS), these disorders differ from PHTS in important respects: PTEN
mutations in PHTS are usually found in all cells, most commonly due to germline transmis-
sion, while PIK3CA mutations in PROS occur in mosaic form, are disproportionately found in
some tissues, and appear not to be compatible with germline transmission. A key phenotypic
difference lies in the increased risk of adult PI3K-associated cancer in PHTS but not PROS.
Additional phenotypic variability in PROS arises from the mosaic nature of the disease and
complicates efforts to establish experimental models. Nevertheless, such models are critically
needed for a better understanding of this rare disorder and for preclinical testing of targeted
therapies.
Study of rare diseases often improves understanding of common disorders and of fundamental
biological mechanisms. Given the critical physiological role of p110a in development and
growth, and its frequent pathological hyperactivation in cancer, this is potentially true for PROS,
too. Conversely, candidate cancer therapeutics targeting the PI3K pathway bring hope for
much needed targeted therapies for PROS, as recently demonstrated in an uncontrolled caseTrends in Molecular Medicine, Month Year, Vol. xx, No. yy https://doi.org/10.1016/j.molmed.2018.08.003 1
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Glossary
Carcinoma: cancer arising from an
epithelium.
CreER: a tamoxifen-dependent Cre
recombinase enzyme commonly
used in mouse genetics to generate
inducible gene expression or
knockout.
CRISPR-based gene editing: a
powerful approach to genetic
engineering, repurposing a bacterial
adaptive immune system
mechanism. It utilizes a gene-speciﬁc
guide RNA, a so-called Cas9
nuclease, and often a nucleic acid
repair template, either inducing
insertion/deletion loss-of-function
mutations or knocking in desired
mutations.
Epidermal nevi: benign localized
overgrowth in the epidermis, either
present at birth or developing during
early childhood.
Exosomes: 40–150 nm vesicles
arising from endosomal
compartments within the cell, and
shown to function in local and distant
intercellular communication.
Germline transmission: the
passing of a genetic mutation from
parent to offspring via a germ cell
(egg or sperm). The mutation is
present in every cell of the offspring.
Induced pluripotent stem cells
(iPSCs): pluripotent stem cells
obtained by direct reprogramming of
differentiated cells. These are
phenotypically indistinguishable from
embryonic stem cells, with the
capacity to yield any cell type in the
human body.
Isogenic: having the same or nearly
identical genetic background.
Mosaicism: the presence of two or
more genetically distinct cell
populations in an individual who
developed from a single fertilized
egg. Genetic mosaicism arises from
the acquisition of postzygotic
mutations.
Neural crest: a transitory
neuroectodermal structure formed
during embryogenesis. It has the
unique property of giving rise to both
neural and mesenchymal cell types,
which are otherwise strictly derived
from either ectodermal or
mesodermal germ layers,
respectively.
Neuroectoderm: derivative of the
ectoderm, one of the threeseries treated with the p110a-speciﬁc inhibitor Alpelisib (BYL719) [4]. Increased awareness of
PROS thus seems timely. This review summarizes current knowledge of p110a activation in
PROS, outlines key unanswered questions, and discusses challenges and opportunities in
disease modeling and evaluation of novel therapies.
Regulation of p110a Activity
The PI3K enzyme ﬁrst identiﬁed was the prototype of what is now known as Class I PI3Ks,
which catalyze conversion of the membrane lipid phosphatidylinositol-4,5-bisphosphate [PI
(4,5)P2] to the second messenger PI(3,4,5)P3 (also known as PIP3). Class I PI3K catalytic
subunits are divided into two subclasses – IA and IB – based on differential usage of regulatory
subunits. Class IA PI3Ks are heterodimers of one of three catalytic subunits (the PIK3CA gene
product p110a, the PIK3CB product p110b, or the PIK3CD product p110d), tightly bound to
one of ﬁve regulatory subunits (the PIK3R1 gene products p85a/p55a/p50a, the PIK3R2
product p85b, or the PIK3R3 product p55g; Figure 1). p110a and p110b are widely expressed,
with p110d predominantly found in leukocytes [5].
p110a signals downstream of plasma membrane-associated tyrosine kinases via recruitment
of the p85 subunit to tyrosine-phosphorylated receptors/receptor-associated adaptor pro-
teins, or by direct binding to the RAS oncogene [5]. p110a activation leads to acute increases in
PIP3 and its degradation product PI(3,4)P2, stimulating membrane recruitment of effector
proteins with PIP3/PI(3,4)P2-binding domains such as the pleckstrin homology domain. Protein
kinase B (AKT) serine/threonine kinases are the best studied PI3K effectors, regulating cell
growth, metabolism, survival, and proliferation [5,6].
PI3K activity is tightly constrained, resulting in transient and localized PIP3 generation. Both
negative feedback by downstream pathway components and the activity of several phospho-
lipid phosphatases are involved in signal termination. Most important of the known lipid
phosphatases is the tumor suppressor PTEN, which converts PIP3 back to PI(4,5)P2 [5].
The importance of exquisite regulation of PI3K signaling is exempliﬁed by the growing number
of genetic disorders known to be caused by mutations in pathway components (Figure 1).
PIK3CA Mutations in Cancer
PI3K activity was linked to pathological cell growth and oncogenesis early after its discovery,
but it was not until 2004 that somatic mutations in PIK3CA were reported in cancers [7].
Through high-throughput sequencing, genetic hyperactivation of PI3K/AKT signaling has
now become recognized as one of the most frequent ‘driver’ mechanisms in many cancers
[5]. Pan-cancer analyses by The Cancer Genome Atlas identiﬁed PIK3CA and PTEN among
the genes most frequently harboring somatic point mutations in more than 12 different solid
tumor types, only behind the tumor suppressor gene TP53 [8,9]. Cancers with a high
prevalence of activating PIK3CA mutations include breast (>30%), endometrial (>30%),
bladder (>20%), colorectal carcinoma (>17%), and head and neck squamous cell carci-
noma (>15%) [8–11].
Cancers may also have gene ampliﬁcation or overexpression of any p110 isoform, but only
p110a is commonly mutationally activated [5]. Mutations span the entire p110a protein except
the RAS-binding domain. Over 80% of PIK3CA mutations cluster at three sites, or ‘hotspots’,
namely, glutamates (E) 542 and 545 in the helical domain, and histidine (H) 1047 near the C
terminus of the kinase domain (Figure 2). These hotspot variants have the most potent effect on
enzymatic activation and downstream biological responses (Table S1 and [11,12]).2 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy
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embryonic germ layers. Gives rise to
neural tissues.
Oncogene-induced senescence: a
tumor-suppressing mechanism
whereby oncogene-induced signaling
triggers irreversible growth arrest.
Postzygotic mutations: DNA
mutations that are not inherited from
either parent, arising instead after the
single-cell zygote stage of
development.
PTEN hamartoma tumor
syndrome: a group of rare
overgrowth disorders caused by
heterozygous loss-of-function
mutations of phosphatase and tensin
homolog (PTEN) in the germline.
Seborrheic keratoses: benign
keratinocyte-derived tumors
developing during adulthood and
appearing as demarcated brownish
plaques predominantly localized in
the head, neck, and trunk.
Self-renewal: the process wherein
cell division leads to regeneration of
the original cell type.
Stemness: a property of stem cells
characterized by a capacity for self-
renewal and an undifferentiated
state. Often used interchangeably
with ‘pluripotency’ in the context of
pluripotent stem cells.
Growth factor
receptor
PI(4,5)P2
p85α
p85β
p55γ
p110α
p110β
p110δ
Class IA PI3K
SelecƟon of AKT substrates
PTEN
PDK1
mTORC2
AKT1
AKT2
AKT3
TSC
Growth
CondiƟon Genes mutated
(no. of cases,
April 2018)
Mosaic (M)
Germline (G),
Cancer (C)
Metabolism Survival ProliferaƟon Glucose uptake
GSK3 BAD FOXO AS160
mTORC1
Cell migraƟon
PI(3,4,5)P3
Plasma membrane
Congenital disorders caused by geneƟc pathway acƟvaƟon
(color-coded according to mutated component)
APDS1: acƟvaƟng p110δ syndrome 1
APDS2: acƟvaƟng p110δ syndrome 2
MEG: megalencephaly
MCAP: megalencephaly-capillary malformaƟon 
syndrome 
MPPH: megalencephaly–polydactyly–
polymicrogyria–hydrocephalus
PHTS: PTEN hamartoma tumor syndrome
PROS: PIK3CA-related overgrowth spectrum
Proteus syndrome
Hypoglycemia with segmental overgrowth
TSC: tuberous sclerosis complex
PIK3CD/p110δ (10–100)
PIK3R1/p85α (10–100)
PIK3R2/p85β (10–100),
AKT3 (10–100),
mTOR (10–100)
PTEN (>1000)
G, C
G, C
G, C
M
M, C
M
G, C
G, M
PIK3CA/p110α (>1000)
AKT1 (100–200)
AKT2 (<10)
TSC1/2 (>1000)
(See figure legend on the bottom of the next page.)
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Although established as cancer drivers, PIK3CA hotspot mutations were also, surprisingly,
identiﬁed in benign skin lesions known as epidermal nevi and seborrheic keratoses [13]. As
in cancer, mutations were only found in the lesions, thus representing another example of
genetic mosaicism. More recently, postzygotic, mosaic, activating PIK3CA mutations were also
identiﬁed in several different forms of segmental overgrowth – that is, asymmetric overgrowth
affecting only some parts of the body [14–16]. Since then, a wide spectrum of such conditions
has been attributed to mosaic genetic activation of p110a. Many affected patients have
patterns of overgrowth previously labeled as speciﬁc syndromes. The resulting fragmented
and inconsistently applied nomenclature complicates classiﬁcation and fails in the face of
intermediate syndromes, leading to the proposed designation of a ‘PIK3CA-related overgrowth
spectrum’, or PROS, to capture the disorders under one label and to reﬂect disease etiology [3].
Clinical Features of PROS
The severity of PROS is highly variable, ranging from localized overgrowth, for example of a
digit, to severe, extensive, and life-threatening overgrowth affecting major vessels and/or
critical organs (Figure 3). PROS may be conceived of as a highly anatomically variable
admixture of overgrown tissues, with vasculature (capillaries, veins and lymphatics) and
adipose tissue often most dramatically affected macroscopically. Many other tissues and
organs, including bone, brain, peripheral nerves, liver, skeletal and cardiac muscle, may also
be affected [3,17,18]. Overgrowth manifests at birth, and progressive overgrowth during
childhood is the norm. Soft-tissue overgrowth sometimes persists in adult life, but this cannot
currently be predicted. Few reports have identiﬁed the identity of mutated cells, with genotyping
usually performed on whole tissue. However, PIK3CA mutations have been detected in
subcultured dermal ﬁbroblasts [14], adipocytes [16], lymphatic endothelial cells [19,20], and
skin (epithelial) keratinocytes [21]. Hotspot PIK3CA mutations are only very rarely identiﬁed in
lymphocyte DNA, even when the overall disease burden is extensive [17,22].
Available therapy for PROS centers on judicious surgical ‘debulking’ of affected regions, with
procedures often hazardous due to abnormal vascular anatomy. Surgical or radiological
blocking of overgrown blood vessels is also important. Current clinical practice and access
of patients to services show major geographical variation, and the unmet need for targeted, less
disﬁguring approaches to therapy is large.
Mutational Spectrum and Genotype–Phenotype Correlation
The severity of PROS is most dependent on the timing and location of the initiating mutation
(Figure 4, Key Figure). The proﬁle of PIK3CA mutations in PROS closely resembles that in
cancer (Figure 2), and hotspot mutations have been suggested to be associated with more
severe, focal overgrowth, with rarer non-hotspot mutations often causing more widely distrib-
uted but milder overgrowth [3,17,22]. However, this fails to explain the full range of observed
phenotypes, with clinical observations and biochemical studies of non-hotspot mutationsFigure 1. Simpliﬁed PI3K Signaling Cascade and Known Clinical Disorders Caused by Genetic Pathway
Activation. Color coding corresponds to the genetic disorders listed. The numbers of reported cases in the table are
approximate. Cancer (C) is used to indicate a known increase in malignancy risk for each disorder. Although cancer itself
features complex genetic mosaicism, in this ﬁgure ‘mosaic’ (M) is restricted to non-cancer mosaicism. AKT, protein kinase
B; FOXO, Forkhead Box O; GSK3, glycogen synthase kinase-3; mTORC, mechanistic target of rapamycin complex; PI3K,
phosphoinositide 3-kinase; PI(3,4,5)P3, phosphatidylinositol-3,4,5-trisphosphate; PI(4,5)P2, phosphatidylinositol-4,5-
bisphosphate; PTEN, phosphatase and tensin homolog.
4 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy
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DistribuƟon of PIK3CA mutaƟons in cancer (COSMIC v85, n = 12 898), May 2018
DistribuƟon of PIK3CA mutaƟons in published PROS cohorts (n = 465)
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Figure 2. The Spectra of Activating PIK3CA Mutations in Cancer and PROS. Most (>80%) activating PIK3CA
mutations in cancer (top) and PROS (bottom) cluster at three hotspots: two glutamic acid (E) residues at codons 542 and
545, and a histidine (H) residue at codon 1047. The most frequent mutations at these sites introduce a strongly positively
charged side chain – lysine (K) at codons 542 and 545 or arginine (R) at codon 1047. With the exception of the RAS-binding
domain (RBD), mutations affect the entire p110a protein, including the adaptor-binding domain (ABD), the C2 domain, the
helical domain, and the kinase domain. These domains are all required for the inhibitory interactions between p110a and its
regulatory subunit. Moreover, the C2 and kinase domains act as lipid-binding interfaces. The distribution of PIK3CA
mutations in cancer were obtained from The Catalogue of Somatic Mutations in Cancer (COSMIC, v85, May 2018) [63],
ﬁltered for variants with 10 counts (except if also found in PROS). PIK3CA mutations in PROS comprise published cases
from larger cohort studies [17,22,64–67]. Note that the x-axis is not numerical and thus does not scale to the distance
between the indicated residues. PROS, PIK3CA-related overgrowth spectrum.suggesting a more graded phenotypic spectrum [12,17,22]. The variability arising from different
anatomical distributions of mutations means that very large studies will be required to address a
possible genotype–phenotype correlation more deﬁnitively.Trends in Molecular Medicine, Month Year, Vol. xx, No. yy 5
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Figure 3. PROS and Some of Its Constituent Disorders. Many overgrowth disorders previously classiﬁed on the basis of anatomical differences are now known
to share a common genetic etiology, namely, postzygotic mosaic, activating mutations in PIK3CA. A selection of older descriptors, many of persisting, practical clinical
value, is shown in the central word cloud, with approximate frequency of use of the terms indicated by font size. PROS is a more general term proposed to reﬂect the
common genetic etiology of these conditions. Representative images capturing different manifestations of PROS are shown, with the causal PIK3CA mutation in each
case indicated below the image. Radiologic images are sections of magnetic resonance images illustrating asymmetric fatty leg overgrowth and inﬁltrating facial
lipomatosis. Hotspot mutations are shown in red. Where people in images are identiﬁable, informed consent has been gained for publication. References are given for
images obtained from published reports [3,14,17]. CLOVES, congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis syndrome; HHML,
hemihypertrophy with multiple lipomatosis; KTS, Klippel–Trenaunay syndrome; MCAP, megalencephaly-capillary malformation syndrome; M-CM, macrocephaly-
capillary malformation syndrome; M-CMTC, megalencephaly-cutis marmorata telangiectatica congenita; PROS, PIK3CA-related overgrowth spectrum.Unanswered Questions about PROS and Activating PIK3CA Mutations
Is PROS Explained by Cell-Autonomous Consequences of PI3K Activation?
Most studies of cancer and PROS have concentrated on cell-autonomous effects of p110a
activation on processes such as cell growth, survival, and migration. However, the mutation
burden in PROS at sites of overgrowth is commonly less than the 50% expected if all cells in the
tissue were heterozygous for the mutation, and overgrown tissue contains multiple cell types of6 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy
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Key Figure
The Phenotypic Effect of Developmental Timing and Location of Foun-
der PIK3CA Mutations
Timing and locaƟon of PIK3CA mutaƟons determine phenotype
Embryo turning
Neural tube closure
Heartbeat
Somitogenesis
Gut formaƟon
Neural plate
PrimiƟve blood islands Limb buds
Endocrine primordia
Lung buds
ConƟnued vasculogenesis/
angiogenesis
Hemispheres
Hand and foot plates
Metanephros
Hematopoiesis Fetal period begins
D20–23 D28 D30–32 D36–38 D49–56
Mosaicism for acƟvaƟng PIK3CA mutaƟons
Figure 4. Timeline of human embryogenesis postgastrulation, highlighting key patterning events and the development of
major organs. The majority of activating PIK3CA mutations in PROS likely arise during this period (D20–D56, gray arrow),
which encompasses the development of most organ systems. The embryo is particularly vulnerable to perturbations
during this phase. In the subsequent fetal period (D57 to birth), organs formed during embryogenesis grow and
differentiate further. The phenotypic heterogeneity in PROS likely reﬂects the variable timing and location of a PIK3CA
mutation during embryogenesis. A mutation arising at early developmental stages is likely to produce disease affecting
multiple organ systems. PROS, PIK3CA-related overgrowth spectrum.different embryonic origin. This raises the possibility, still to be tested, that PIK3CA mutation-
positive cells exert growth-promoting effects on adjacent or distant cells. This could involve
cell–cell interactions, paracrine growth factors, exosomes, and/or alterations to the extracel-
lular matrix.
What Explains the Tissue-Selective Overgrowth of PROS?
The initial mutation driving PROS is assumed to arise stochastically, and therefore the proba-
bility of different developmental lineages being affected should reﬂect the number of cells of
each lineage present in the embryo at the time of mutation. PROS, however, exhibits apparent
skewing in the pattern of overgrowth among tissues, with mesoderm-derived tissues (e.g.,
adipose tissue, vasculature, muscle, bone) and neuroectoderm-derived tissues (e.g., brain,Trends in Molecular Medicine, Month Year, Vol. xx, No. yy 7
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Human gastrulaƟon
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Figure 5. Apparent Skewing of Hotspot PIK3CA Mutations toward Some Embryonic Lineages. Shortly after fertilization, the human embryo resembles a
ﬂattened cellular disk known as the epiblast. Between 15 and 21 days postfertilization (dpf), the epiblast transforms into the three germ layers (ectoderm, mesoderm,
and endoderm) in the process of gastrulation. This involves carefully balanced morphogen gradients and intricate crosstalk among the developing germ layers, acting on
one another to instruct lineage speciﬁcation. The ectoderm gives rise to the epidermis (skin) and nervous system (neuroectoderm), including neural crest derivatives (e.
g., cephalic connective tissue). The mesoderm is patterned into three subtypes (shown in the transverse section of the developing embryo), which combined develop
into a variety of tissues, including bone, cartilage, connective and adipose tissue, smooth and skeletal muscle, the vascular system, heart, gut and lung walls, blood
cells, kidneys, and gonads. The endoderm lineage speciﬁes the gastrointestinal and respiratory systems, the epithelial lining of the bladder and urethra, as well as many
endocrine glands. In PROS, it appears that hotspot PIK3CA mutations such as H1047R are not present in endodermal tissue derivatives, and further exhibit a skewing
away from blood cells. Note that biopsies from internal organs are rarely available for direct genotyping, and inferences about mutation distribution in such cases are
largely based on the macroscopic pattern of overgrowth. PROS, PIK3CA-related overgrowth spectrum.cephalic connective tissue) prominently affected macroscopically (Figure 5). There is much less
macroscopic involvement of endoderm-derived structures (e.g., pancreas, liver), and little
evidence of epithelial overgrowth beyond epidermal nevi and seborrheic keratoses, both of
neuroectodermal origin [23]. The extremely low burden of PIK3CA hotspot mutations in blood,
in contrast to non-hotspot variants, which are not infrequently detected in many tissues,8 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy
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processes such as skewing of developmental cell fate decisions, lineage-speciﬁc positive or
negative selection for PIK3CA-mutant cells, and/or alterations of stem cell dynamics. For
instance, hotspot PIK3CA variants may lead to lineage-speciﬁc cell loss during or after
differentiation due to mechanisms such as oncogene-induced senescence, which is known
to occur in cells with strong activation of PI3K signaling [24]. Hyperactivation of PI3K signaling in
stem cells may also lead to attenuation or ‘exhaustion’ of stem cells’ regenerative capacity, a
phenomenon best studied in hematopoietic stem cells [25].
Increased PI3K signaling may affect stemness and/or early lineage determination of pluripo-
tent stem cells (PSCs), and even subtle effects could have a major inﬂuence on the PROS
phenotype. PI3K/AKT signaling contributes to self-renewal and stemness in models of early
development [26,27], but understanding of dose-dependent effects on human cell fate deci-
sions and crosstalk with key ‘stemness’ pathways is sparse. The development of human stem
cell-based models with activating PIK3CA mutations will permit interrogation of the apparent
lineage skewing observed in vivo. The potential role of neural crest stem cells in PROS will be of
particular interest given their ability to generate neuroectodermal and mesodermal tissue
derivatives, corresponding to tissues most commonly overgrown in PROS.
It is important to stress that most diagnostic testing is currently undertaken on accessible areas
of macroscopic overgrowth rather than on tissues from internal organs, especially if not frankly
enlarged, creating an inevitable bias. Apparent tissue-selective overgrowth may also partly
reﬂect nonuniform PIK3CA gene expression, with the pancreas and liver having more than ﬁve
times lower mRNA expression than arteries, nerves, adipose tissue, uterus, and breast [28].
Moreover, tissues also differ in their capacity to expand as part of physiological adaptation.
Adipose tissue and vessels, for example, may dramatically grow and later regress in the face of
a transient positive energy balance or tissue injury, and this inherent plasticity may be ampliﬁed
into greater overgrowth by an endogenous trophic stimulus. More systematic tissue sampling
will be needed, ideally with single-cell sequencing, to form an unbiased view of PIK3CA
mutation distribution in PROS.
Why Is Cancer Not More Common in PROS?
To date, the only malignancy reported in PROS is Wilms tumor (nephroblastoma), an embryonal
pediatric cancer identiﬁed in four of around 200 patients with PROS [29]. Thus, although
PIK3CA mutations are very common in cancers, none of the cancer types enriched for such
mutations (e.g., endometrial and breast) have been reported in PROS. This may reﬂect distinct
mutation tissue distributions in PROS and cancer. Indeed, as mentioned earlier, most macro-
scopic overgrowth in PROS occurs in mesodermal and neuroectodermal derivatives (Figure 5),
while PIK3CA-associated cancers most commonly arise in ectodermal or endodermal epithe-
lia. Neuroectodermal and mesodermal cancers show very low occurrence, if any, of activating
PIK3CA mutations [10].
It is also important to emphasize that when denoting a cancer-associated mutation, a cancer
‘driver’ implies that it confers a selective growth advantage at some point during cancer
development, and not that it is sufﬁcient for cancer initiation or maintenance [30]. This is
illustrated by murine cancer models which demonstrate that activating Pik3ca mutations
usually require cooperating genetic lesions to induce cancer [31–33]. The cellular/tissue
context of the mutations is also likely to be an important determinant of their effect on cell
behavior, with evidence that even within a single tissue such as the mammary gland, the effect
of the hotspot variant Pik3ca-H1047R is dictated by the cell of origin [33,34].Trends in Molecular Medicine, Month Year, Vol. xx, No. yy 9
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In marked contrast to PROS, PHTS predisposes to several cancers associated with PI3K
activation [35], including breast, endometrial, and colorectal carcinomas. This may reﬂect
expression of the PTEN mutation in all cells, or the fact that PTEN is not speciﬁc for p110a-
derived PIP3. Instead, it opposes signaling by any Class I PI3K isoform. Moreover, PTEN has
nuclear and lipid phosphatase-independent activities [36,37], although their role in the PHTS
phenotype is unclear. A further interesting possibility is that different proﬁles or strengths of
aberrant PI3K activation inﬂuence cancer risk. Side-by-side comparisons have not been
published, but baseline pathway activation by PIK3CA mutations appears higher than that
conferred by heterozygous PTEN loss of function, which results in only modestly increased
basal PI3K signaling in some contexts [38,39], and no discernibly increased signaling in others
[39,40]. Dose-dependent effects of PI3K activation have also been documented in the myriad
of cellular studies comparing PIK3CA mutations of different potency (see Table S1 and [11,12]),
as well as in mouse models of PIK3CA-driven cancer where tumorigenesis is often only
observed upon transgenic overexpression of mutant PIK3CA [32–34,41–49]. Thus, under-
standing the mechanisms determining differential cancer risk in PHTS and PROS may yield new
biological insights into Class IA PI3K and will be important in guiding personalized therapy.
Will PI3K Pathway Inhibition Be Effective in PROS?
Downstream inhibition of the PI3K pathway by targeting of mechanistic target of rapamycin
(mTOR) is currently possible with agents such as Sirolimus, already used in clinical practice for
prevention of organ allograft rejection, for the treatment of autoimmune disorders and some
cancers, and, more recently, for precision therapy for tuberous sclerosis complex [50].
Published and unpublished cases suggest that sirolimus may exert some beneﬁcial effects
in PROS, and its use on compassionate grounds is consequently spreading in clinical practice.
Nevertheless, the lack of randomization, blinding and placebo control in current studies means
that its true efﬁcacy is currently difﬁcult to assess.
A more targeted option for therapy would be speciﬁc inhibition of p110a. Several small-molecule
inhibitors of p110a are in development for oncology indications (Table S2), but have been
ineffective as monotherapy in cancer. One problem has been drug intolerance, especially at
the high doses routinely used in cancer trials. Nevertheless, the palette of available PI3K inhibitors
can potentially be repurposed for treatment of PROS, where low-dose single-agent therapy may
sufﬁce. While no p110a-speciﬁc inhibitors have yet been approved for clinical use, one promising
option is the ATP-competitive p110a inhibitor Alpelisib (BYL719; Novartis). A low dose of Alpelisib
used on compassionate grounds was shown in an uncontrolled case series to have striking effects
in a cohort of 19 PROS patients, several with life-threatening complications [4]. The low dose of
Alpelisib provoked few side effects and did not impair linear growth of the often young patients [4].
This early indication of possible efﬁcacy with good tolerability urgently requires assessment in
formal trials. It is very encouraging evidence that a therapeutic window may be found, permitting
the needed lifelong treatment which is likely to be growth suppressive rather than curative [51].
Previous studies have shown that insulin/PI3K/mTOR inhibition prolongs lifespan across a range
of evolutionarily distinct organisms [52], and low-dose p110a inhibition in obese mice and
monkeys increases energy expenditure and reduces adiposity, with long-term metabolic beneﬁts
[53,54]. These observations suggest that there may even be collateral beneﬁts of low-dose PI3K
inhibition beyond mitigating disease-speciﬁc features of PROS.
Models of PIK3CA Activation and PROS: Challenges and Opportunities
Faithful experimental models of PROS, ideally spanning a spectrum of mutations, are required
to obtain mechanistic insight into the underlying disease pathology and to test proposed10 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy
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(Table 1), and these illustrate the complexity of modeling mosaic disease, arising from the
variability in time and place of the initiating mutation. Important decisions to be made in PROS
modeling include (i) whether to employ global versus tissue- or lineage-restricted Pik3ca
mutation; (ii) which Pik3ca allele to use; (iii) whether to activate Pik3ca in all cells in the tissue
studied or instead to use subthreshold induction to yield mosaic activation; and, critically (iv)
which time window to use for induction.
Mice with constitutively expressed Pik3ca-H1047R from the endogenous locus die at E9.5–
E10.5 [42,55], consistent with Happle’s hypothesis that many mosaic disease variants would
be lethal in the germline [56]. It is plausible that some of the less common PIK3CA alleles are
compatible with embryonic survival, given their detection in many tissues in PROS patients, but
this has not yet been assessed. To overcome early lethality and to mimic PROS, varying levels
of Pik3ca-H1047R mosaicism in mesoderm have been generated using inducible CreER
expression driven by the T Brachyury promoter [57]. Mutant animals developed vascular
abnormalities remarkably similar to human venous malformations, with severity relating to
mutation burden, but surprisingly no other tissue overgrowth was seen. It is not clear whether
this reﬂects biological differences between mice and humans, the promoter used, or the timing
of mutation induction.
The importance of mutation timing and cellular context has been shown in studies modeling
Pik3ca-driven brain overgrowth in mice, using Cre-dependent transgenic PIK3CA-H1047R or
endogenous Pik3ca-E545K expression [58]. These studies demonstrated that brain over-
growth requires p110a activation during embryogenesis, while postnatal induction of
Pik3ca-E545K is sufﬁcient to cause neurological dysfunction in animals with normal brain size
[58]. Other mouse models featuring inducible whole-body Pik3ca-H1047R expression have
yielded somewhat contradictory results, whether expressing the mutant allele transgenically
[59] or from the endogenous Pik3ca locus [42,60] (Table 1). The timing and strength of mutant
induction have emerged as key variables affecting disease severity, but do not fully explain the
observed differences. A recently developed model utilizing an inducible, artiﬁcially activated
p110a variant did develop the majority of phenotypes observed in PROS [4], despite postnatal
induction. The variant used confers stronger pathway activation than natural hotspot PIK3CA
mutants, suggesting that mice differ from humans in requiring a higher strength of aberrant
PI3K signaling to express the full somatic growth phenotype of PROS [4].
Emerging Opportunities for PROS Modeling
Aberrant growth in PROS begins before birth, so study of mosaic embryonic p110a activation
is important. Given species differences in early development, interrogation of developmental
functions of p110a in human models is highly desirable. Recent methodological advances in
stem cell science offer many new experimental options. Reprogramming of a mosaic culture of
cells from patients with PROS to induced PSCs (iPSCs) may yield an initial admixture of
mutant and wild-type cells, from which isogenic clonal wild-type and mutant iPSCs may
simultaneously be established. Alternatively, clustered regularly interspaced short palin-
dromic repeats (CRISPR)-based gene editing can be used to engineer normal human
PSCs with different activating PIK3CA mutations, generating an allelic series on an isogenic
background. In turn, these cells can be used to obtain 3D or 4D ‘multiorgan’ systems, bridging
the gap between 2D cellular studies and animal-based models [61]. Mosaicism can also be
modeled in a controlled manner by mixing wild-type and mutant human PSCs, which could be
labeled to permit visualization of population dynamics during differentiation in vitro or in vivo.
Inducible systems will further allow individual PIK3CA mutations to be expressed at differentTrends in Molecular Medicine, Month Year, Vol. xx, No. yy 11
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Table 1. Activating Pik3ca Mutations in Mouse Models of Relevance to PROS with Information about Expression Strategy and a Summary of Key
Findingsa
Mouse model Expression Time of induction Lineage/tissue
speciﬁcity
Pathology Refs
Cre-del;
Pik3caWT/H1047R
hACTB-Flpe;
Pik3caWT/H1047R
Endogenous Congenital Ubiquitous Embryonic lethality (E9.5–E10.5) with failed turning,
absence of several somites, failed neural tube closure,
vascular defects, and impaired hematopoiesis.
[55]
[42]
T-CreER;
Pik3caWT/H1047R
(MosMes-
Pik3caH1047R)
Endogenous E7.5–E10.5 Mesoderm Subcutaneous vascular malformations at birth at multiple
sites. Impaired survival upon strong induction. No somatic
overgrowth.
[57]
hGFAP-Cre;
Rosa26-rtTA; TetO-
PIK3CAH1047R
Transgenic Congenital or P1 Subset of neural
progenitors
(telencephalon
from E13.5)
Congenital expression led to brain malformations and
death of pups before weaning. Postnatal induction did not
induce anatomical brain abnormalities.
[58]
hGFAP-Cre;
Pik3caWT/E545Kb
Endogenous Congenital Subset of neural
progenitors
(telencephalon
from E13.5)
Viable with large dysplastic brains but no gross brain
malformations.
[58]
Nestin-Cre;
Pik3caWT/E545Kb
Nestin-CreER;
Pik3caWT/E545Kb
Endogenous Congenital or
from P1
Neural
progenitors
(telencephalon
from E11)
Embryonic induction increased brain size with dysplasia.
Postnatal induction produced no anatomical brain
abnormalities but did cause epilepsy which was reversible
by pan-PI3K inhibition.
[58]
Tie2-Cre;
Pik3caWT/H1047R
Tie2-Cre; Rosa26-
Pik3caH1047R
Endogenous or
transgenic
Congenital Endothelial cells Embryonic lethality (E10–E11.5) due to vascular defects
and impaired hematopoiesis. Linear growth retarded.
Growth and vascular phenotype rescued by p110a-
speciﬁc inhibitor administered at E7.5–E9.5.
[55]
[59]
[62]
Pdgfb-CreER;
Pik3caWT/H1047R
Endogenous P1 Endothelial cells Retinal endothelial cell hyperplasia, absent pericytes, and
loss of arteriovenous identity markers at P6. Reversed by
mTOR inhibition with rapamycin.
[57]
Cdh5-CreER;
Rosa26-
Pik3caH1047R
Transgenic 8–10 weeks old Endothelial cells Mortality within 15 days of induction with cardiac
degeneration. Intramuscular expression caused bleeding
from vascular malformations, and increased vessel
density. Reduced with either dual PI3K/mTOR or mTOR
inhibition.
[62]
CAG-CreER;
Rosa26-
Pik3caH1047R
UBC-CreER;
Rosa26-
Pik3caH1047R
Transgenic 3 weeks old Ubiquitous Venous malformations with endothelial cell hyperplasia
and death within 50 days of induction. Transplanted
malformations responsive to p110a or mTOR inhibition.
[59]
UBC-CreER;
Pik3caWT/H1047R
CAG-Flpe-ER;
Pik3caWT/H1047Rc
Endogenous 6–8 weeks and
15 weeks old
[60]
8 weeks old [42]
Ubiquitous Hypoglycemia, hypoinsulinemia, organomegaly, and
increased vascularization within 3 weeks of induction;
death within 100 days [60].
Sudden death for unknown reasons (median survival 220
days after induction) [42].
[60]
[42]
aAbbreviations: 4-OHT, 4-hydroxytamoxifen; Cdh5, Cadherin 5; Cre-del, Cre deleter; ER, estrogen receptor; Flpe, ﬂippase; hACTB, human b-actin; hGFAP, human glial
ﬁbrillary acidic protein; MosMes, mosaic mesoderm; P#, postnatal day; Pdgfb, platelet-derived growth factor b; rtTA, reverse transcription activator (‘tet-on’ system); T,
T Brachyury; TetO, bacterial tet operator site; Tie2, tunica intima endothelial kinase 2; UBC, ubiquitin.
bPik3ca expression from targeted allele disrupted in cells without Cre expression.
cHypomorph with reduced Pik3ca expression until neo cassette removal.time points and can be used to address questions about negative selection during lineage
speciﬁcation. Importantly, PSCs can be used to generate all the cell types affected in PROS,
enabling studies of cell-speciﬁc pathology as well as preclinical drug testing.12 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy
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Box 1. Clinician’s Corner
 Tissue growth is regulated by hormones and growth factors. Many of these act on cell surface receptors to trigger
activation of intracellular signaling pathways. One major pathway includes the enzyme PI3K. The PIK3CA gene
encodes a critical component of this enzyme.
 Powerful evidence for the importance of PI3K in growth regulation is the high frequency of activating PIK3CA
mutations in solid cancers. For this reason, major effort has been invested over 15 years in generating potential
cancer drugs to inhibit the abnormally activated enzyme. These drugs, used at high doses, have shown only modest
beneﬁts, with high rates of side effects in cancer trials to date.
 More recently, cancer-associated PIK3CA mutations have also been shown to cause a wide range of clinical
overgrowth disorders, many with different syndromic names based on the pattern of overgrowth. The causal PIK3CA
mutations almost invariably are not inherited, but instead arise during development and thus are found in only some
parts of the body. An asymmetric, patchy distribution of excess growth is a hallmark of this group of syndromes, now
suggested to be uniﬁed by the label PIK3CA-related overgrowth syndrome (PROS). Overgrowths of fat tissue, blood
vessels, skin, or the brain are particularly prominent.
 The need for novel medical therapies is large. Major clinical complications in PROS arise from vascular crises and
compressive phenomena, and until now the mainstay of therapy has been debulking procedures. Evidence is now
emerging that low doses of PI3K inhibitors, initially developed for cancer, may be highly beneﬁcial in PROS, limiting
excess soft-tissue growth and potentially reducing need for surgery. Thus, controlled trials are urgently required.
 The study of isolated PIK3CA activation in PROS also offers the opportunity to learn more about the fundamental role
of PI3K in human development and cancer. In addition to detailed prospective studies of affected patients, their
tissues and cells, creation of experimental disease models will be of great importance. Aided by advanced genome
editing technologies, animal and stem cell models are now rapidly being developed to help address key unanswered
questions.
Outstanding Questions
Is PROS adequately explained by
cell-autonomous actions of
PIK3CA mutations? Clinical obser-
vations in PROS suggest circumstan-
tially that PIK3CA mutant cells might
exert paracrine or remote effects on
unaffected cells, with consequences
for disease outcome. This remains to
be substantiated, but could involve
signal propagation through secreted
biomolecules or exosomes.
What explains the tissue-selective
overgrowth of PROS? The apparent
sparing of endoderm and hematopoi-
etic lineages suggests negative as well
as positive selection acting on cells
with mutations. Approaches such as
stem cell-based modeling using
admixtures of mutant and wild-type
cells, and single-cell sequencing to
reconstruct cell lineages in vivo offer
great potential for better understand-
ing of the cellular ecology of PROS.
Why does PROS not confer a
greater risk of known PIK3CA-
associated cancers? To date, PROS
patients have not been reported to
exhibit any increased risk of PIK3CA-
associated adult cancers. This might
be explained by differences in the tis-
sues and cell lineages that are
affected, or may reﬂect the importance
of cooperating mutations for cancer
development. Better understanding
of context-dependent consequences
of chronic PIK3CA activation could
offer fundamental insights into the
pathogenesis of PIK3CA-associated
cancers.
What explains the different clinical
consequences of PTEN loss and
PIK3CA activation? They may be
explained by p110a-independent
PI3K activity, by loss of non-lipid phos-
phatase roles of PTEN, or by differen-
ces in the pattern of deranged PI3K
signaling resulting from PTEN loss and
PIK3CA activation.
Will repurposed PI3K cancer ther-
apies be clinically useful as ‘preci-
sion’ treatments for PROS? Recent
reports suggest that use of low doses
of the p110a-speciﬁc inhibitor AlpelisibConcluding Remarks
The discovery of activating PIK3CA mutations in PROS has not only yielded a new target for
much-needed precision therapies, but has also exposed gaps in our understanding of PI3K
signaling in human cancer and embryonic development (see Outstanding Questions and
Box 1). A better understanding of how PI3K pathway responses differ depending on signaling
dosage and cellular context may even suggest novel therapeutic strategies in PI3K-driven
cancers. Monotherapy with high-dose PI3K-speciﬁc inhibitors has fared poorly in oncology
trials, and strategies in which PI3K inhibition is more closely tailored to the underlying pertur-
bation may be worthy of assessment [51]. Key insights are expected from single-cell studies of
human PROS, and from comparison of spatiotemporal dynamics of PI3K signaling in different
PI3K-related genetic diseases. Temporally controlled cell type-speciﬁc expression of mutant
PIK3CA alleles in animal models, allied to creative use of engineered human stem cells and
organoids, is likely to be an important tool. Such efforts will require cross-discipline collabo-
rations including basic and translational scientists focusing on signaling, cancer, and
development.
Acknowledgments
We thank Rachel Knox for help assembling Figure 2. R.K.S. and R.R.M. are supported by the Wellcome Trust (grants
210752/Z/18/Z and 105371/Z/14/Z, respectively) and by the UK NIHR Cambridge Biomedical Research Centre. B.V. is
supported by Cancer Research UK (C23338/A15965), PTEN Research and the UK NIHR University College London
Hospitals Biomedical Research Centre.
Supplemental Information
Supplemental information associated with this article can be found online at https://doi.org/10.1016/j.molmed.2018.08.
003.
References
may yield remarkable clinical improve-
ments in PROS patients, with addi-
tional evidence for lesser beneﬁts1. Whitman, M. et al. (1988) Type I phosphatidylinositol kinase
makes a novel inositol phospholipid, phosphatidylinositol-3-
phosphate. Nature 332, 644–6462. Hollander, M.C. et al. (2011) PTEN loss in the continuum of
common cancers, rare syndromes and mouse models. Nat.
Rev. Cancer 11, 289–301Trends in Molecular Medicine, Month Year, Vol. xx, No. yy 13
TRMOME 1374 No. of Pages 15
from mTOR inhibition with Sirolimus.
Controlled clinical trials with prespeci-
ﬁed end points are urgently needed to
conﬁrm these ﬁndings and to establish
longer-term outcomes.3. Keppler-Noreuil, K.M. et al. (2014) Clinical delineation and natural
history of the PIK3CA-related overgrowth spectrum. Am. J. Med.
Genet. A 164, 1713–1733
4. Venot, Q. et al. (2018) Targeted therapy in patients with PIK3CA-
related overgrowth syndrome. Nature 558, 540–546
5. Thorpe, L.M. et al. (2015) PI3K in cancer: divergent roles of
isoforms, modes of activation and therapeutic targeting. Nat.
Rev. Cancer 15, 7–24
6. Manning, B.D. and Toker, A. (2017) AKT/PKB signaling: navigat-
ing the network. Cell 169, 381–405
7. Samuels, Y. et al. (2004) High frequency of mutations of the
PIK3CA gene in human cancers. Science 304, 554
8. Kandoth, C. et al. (2013) Mutational landscape and signiﬁcance
across 12 major cancer types. Nature 503, 333–339
9. Lawrence, M.S. et al. (2014) Discovery and saturation analysis of
cancer genes across 21 tumour types. Nature 505, 495–501
10. Millis, S.Z. et al. (2016) Landscape of phosphatidylinositol-3-
kinase pathway alterations across 19 784 diverse solid tumors.
JAMA Oncol. 2, 1565–1573
11. Zhang, Y. et al. (2017) A Pan-Cancer proteogenomic atlas of
PI3K/AKT/mTOR pathway alterations. Cancer Cell 31, 820–832.
e3
12. Dogruluk, T. et al. (2015) Identiﬁcation of variant-speciﬁc func-
tions of PIK3CA by rapid phenotyping of rare mutations. Cancer
Res. 75, 5341–5354
13. Hafner, C. et al. (2007) Oncogenic PIK3CA mutations occur in
epidermal nevi and seborrheic keratoses with a characteristic
mutation pattern. Proc. Natl. Acad. Sci. U. S. A. 104,
13450–13454
14. Lindhurst, M.J. et al. (2012) Mosaic overgrowth with ﬁbroadipose
hyperplasia is caused by somatic activating mutations in PIK3CA.
Nat. Genet. 44, 928–933
15. Rivière, J.-B. et al. (2012) De novo germline and postzygotic
mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of
related megalencephaly syndromes. Nat. Genet. 44, 934–940
16. Kurek, K.C. et al. (2012) Somatic mosaic activating mutations in
PIK3CA cause CLOVES syndrome. Am. J. Hum. Genet. 90,
1108–1115
17. Mirzaa, G. et al. (2016) PIK3CA-associated developmental dis-
orders exhibit distinct classes of mutations with variable expres-
sion and tissue distribution. JCI Insight 1, e87623
18. Leiter, S.M. et al. (2017) Hypoinsulinaemic, hypoketotic hypogly-
caemia due to mosaic genetic activation of PI3-kinase. Eur. J.
Endocrinol. 177, 175–186
19. Boscolo, E. et al. (2015) AKT hyper-phosphorylation associated
with PI3 K mutations in lymphatic endothelial cells from a patient
with lymphatic malformation. Angiogenesis 18, 151–162
20. Osborn, A.J. et al. (2015) Activating PIK3CA alleles and lymphan-
giogenic phenotype of lymphatic endothelial cells isolated from
lymphatic malformations. Hum. Mol. Genet. 24, 926–938
21. Groesser, L. et al. (2012) FGFR3, PIK3CA and RAS mutations in
benign lichenoid keratosis. Br. J. Dermatol. 166, 784–788
22. Kuentz, P. et al. (2017) Molecular diagnosis of PIK3CA-related
overgrowth spectrum (PROS) in 162 patients and recommenda-
tions for genetic testing. Genet. Med. 19, 989–997
23. Sarnat, H.B. and Flores-Sarnat, L. (2013) Genetics of neural crest
and neurocutaneous syndromes. In Handbook of Clinical Neurol-
ogy, (1st ed) pp. 309–314, Elsevier
24. Kim, J.-S. et al. (2007) Activation of p53-dependent growth
suppression in human cells by mutations in PTEN or PIK3CA.
Mol. Cell. Biol. 27, 662–677
25. Baumgartner, C. et al. (2018) An ERK-dependent feedback
mechanism prevents hematopoietic stem cell exhaustion. Cell
Stem Cell 22, 879–892.e6
26. Yu, J.S. and Cui, W. (2016) Proliferation, survival and metabolism:
the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate
determination. Development 143, 3050–306014 Trends in Molecular Medicine, Month Year, Vol. xx, No. yy27. Yilmaz, A. et al. (2018) Deﬁning essential genes for human plu-
ripotent stem cells by CRISPR–Cas9 screening in haploid cells.
Nat. Cell Biol. 20, 610–619
28. Carithers, L.J. et al. (2015) A novel approach to high-quality
postmortem tissue procurement: the GTEx project. Biopreserv.
Biobank. 13, 311–319
29. Gripp, K.W. et al. (2016) Nephroblastomatosis or Wilms tumor in
a fourth patient with a somatic PIK3CA mutation. Am. J. Med.
Genet. A 170, 2559–2569
30. Stratton, M.R. et al. (2009) The cancer genome. Nature 458,
719–724
31. Robinson, G. et al. (2012) Novel mutations target distinct sub-
groups of medulloblastoma. Nature 488, 43–48
32. Green, S. et al. (2015) PIK3CAH1047R accelerates and enhances
KRASG12D-driven lung tumorigenesis. Cancer Res. 75,
5378–5391
33. Van Keymeulen, A. et al. (2015) Reactivation of multipotency by
oncogenic PIK3CA induces breast tumour heterogeneity. Nature
525, 119–123
34. Koren, S. et al. (2015) PIK3CAH1047R induces multipotency and
multi-lineage mammary tumours. Nature 525, 114–118
35. De Santis, M. et al. (2017) PI3K signaling in tissue hyper-prolifer-
ation: from overgrowth syndromes to kidney cysts. Cancers
(Basel) 9, 30
36. Shen, W.H. et al. (2007) Essential role for nuclear PTEN in main-
taining chromosomal integrity. Cell 128, 157–170
37. Song, M.S. et al. (2011) Nuclear PTEN regulates the APC-CDH1
tumor-suppressive complex in a phosphatase-independent man-
ner. Cell 144, 187–199
38. Horie, Y. et al. (2004) Hepatocyte-speciﬁc Pten deﬁciency results
in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest.
113, 1774–1783
39. Papa, A. et al. (2014) Cancer-associated PTEN mutants act in a
dominant-negative manner to suppress PTEN protein function.
Cell 157, 595–610
40. Chen, Z. et al. (2005) Crucial role of p53-dependent cellular
senescence in suppression of Pten-deﬁcient tumorigenesis.
Nature 436, 725–730
41. Sheen, M.R. et al. (2016) Constitutively activated PI3K acceler-
ates tumor initiation and modiﬁes histopathology of breast can-
cer. Oncogenesis 5, e267
42. Berenjeno, I.M. et al. (2017) Oncogenic PIK3CA induces centro-
some ampliﬁcation and tolerance to genome doubling. Nat. Com-
mun. 8, 1773
43. Engelman, J.A. et al. (2008) Effective use of PI3K and MEK
inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine
lung cancers. Nat. Med. 14, 1351–1356
44. Meyer, D.S. et al. (2011) Luminal expression of PIK3CA mutant
H1047R in the mammary gland induces heterogeneous tumors.
Cancer Res. 71, 4344–4351
45. Liu, P. et al. (2011) Oncogenic PIK3CA-driven mammary tumors
frequently recur via PI3K pathway-dependent and PI3K pathway-
independent mechanisms. Nat. Med. 17, 1116–1120
46. Hanker, A.B. et al. (2013) Mutant PIK3CA accelerates HER2-
driven transgenic mammary tumors and induces resistance to
combinations of anti-HER2 therapies. Proc. Natl. Acad. Sci. U. S.
A. 110, 14372–14377
47. Yueh, A.E. et al. (2016) Colon cancer tumorigenesis initiated by
the H1047R mutant PI3K. PLoS One 11, 1–11
48. Yuan, W. et al. (2012) Conditional activation of Pik3caH1047R in a
knock-in mouse model promotes mammary tumorigenesis and
emergence of mutations. Oncogene 32, 318–326
49. Tikoo, A. et al. (2012) Physiological levels of Pik3caH1047R muta-
tion in the mouse mammary gland results in ductal hyperplasia
and formation of ERa-positive tumors. PLoS One 7, 1–13
50. Fruman, D.A. and Rommel, C. (2014) PI3K and cancer: lessons,
challenges and opportunities. Nat. Rev. Drug Discov. 13, 140–156
TRMOME 1374 No. of Pages 1551. Semple, R.K. and Vanhaesebroeck, B. (2018) Lessons for cancer
drug treatment from tackling a non-cancerous overgrowth
syndrome. Nature 558, 523–525
52. Kenyon, C.J. (2010) The genetics of ageing. Nature 467,
622–622
53. Ortega-Molina, A. et al. (2015) Pharmacological inhibition of PI3K
reduces adiposity and metabolic syndrome in obese mice and
rhesus monkeys. Cell Metab. 21, 558–570
54. Lopez-Guadamillas, E. et al. (2016) PI3Ka inhibition reduces
obesity in mice. Aging (Albany, NY) 8, 2747–2753
55. Hare, L.M. et al. (2015) Heterozygous expression of the onco-
genic Pik3caH1047R mutation during murine development results
in fatal embryonic and extraembryonic defects. Dev. Biol. 404,
14–26
56. Happle, R. (1987) Lethal genes surviving by mosaicism: a possi-
ble explanation for sporadic birth defects involving the skin. J. Am.
Acad. Dermatol. 16, 899–906
57. Castillo, S.D. et al. (2016) Somatic activating mutations in Pik3ca
cause sporadic venous malformations in mice and humans. Sci.
Transl. Med. 8, 332ra43
58. Roy, A. et al. (2015) Mouse models of human PIK3CA-related
brain overgrowth have acutely treatable epilepsy. Elife 4, 12703
59. Castel, P. et al. (2016) Somatic PIK3CA mutations as a driver of
sporadic venous malformations. Sci. Transl. Med. 8, 332ra4260. Kinross, K.M. et al. (2015) Ubiquitous expression of the
Pik3caH1047Rmutation promotes hypoglycemia, hypoinsulinemia,
and organomegaly. FASEB J. 29, 1426–1434
61. Liu, C. et al. (2018) Modeling human diseases with induced
pluripotent stem cells: from 2D to 3D and beyond. Development
145, dev156166
62. di Blasio, L. et al. (2018) PI3K/mTOR inhibition promotes the
regression of experimental vascular malformations driven by
PIK3CA-activating mutations. Cell Death Dis. 9, 45
63. Forbes, S.A. et al. (2017) COSMIC: somatic cancer genetics at
high-resolution. Nucleic Acids Res. 45, D777–D783
64. Hucthagowder, V. et al. (2017) Utility of clinical high-depth next
generation sequencing for somatic variant detection in the
PIK3CA-related overgrowth spectrum. Clin. Genet. 91, 79–85
65. Yeung, K.S. et al. (2017) Somatic PIK3CA mutations in seven
patients with PIK3CA-related overgrowth spectrum. Am. J. Med.
Genet. A 173, 978–984
66. Chang, F. et al. (2017) Molecular diagnosis of mosaic overgrowth
syndromes using a custom-designed next-generation sequenc-
ing panel. J. Mol. Diagn. 19, 613–624
67. Wu, J. et al. (2018) An investigation of PIK3CA mutations in
isolated macrodactyly. J. Hand Surg. Eur. Vol.
1753193418770366Trends in Molecular Medicine, Month Year, Vol. xx, No. yy 15
